Genomic Vision announces the approval by its General Meeting of all the resolutions recommended by the Management Board

Bagneux (France), August 10, 2020 - Genomic Vision (FR0011799907 – GV), a company specialized in in-vitro diagnostic (IVD) tests for the early detection of cancers and genetic diseases, and in the development of applications for life sciences research (LSR), informs its shareholders that Combined Shareholders’ Meeting held today in camera, was able to deliberate as the required quorum was reached.

The shareholders of Genomic Vision voted in favour of all the resolutions presented in line with the recommendations of the Management Board.

In particular, the meeting approved the setting up of a financing line with Winance, the Company’s financial partner, through a reserved issuance of convertible notes with warrants (OCABSA) for a maximum amount of €12 million in order to secure the Company’s potential needs in terms of investment and financing of growth over the next 2 or 3 years.

Genomic Vision would like to thank all its shareholders for their commitment and support.

The minutes of the combined shareholders’ meeting of August 10, 2020 will be available within the legal deadlines on the Company’s website, under the heading Investors/General Meetings.

***

ABOUT GENOMIC VISION

GENOMIC VISION is a biotechnology company developing products and services dedicated to the analysis (structural and functional) of genome modifications as well as to the quality and safety control of these modifications, in particular in genome editing technologies and biomanufacturing processes. Genomic Vision proprietary tools, based on DNA combing technology and artificial intelligence, provide robust quantitative measurements needed to high confidence characterization of DNA alteration in the genome. These tools are mainly used for monitoring DNA replication in cancerous cell, for early cancer detection and the diagnosis of genetic diseases. Based near Paris, in Bagneux, the Company has approximately 30 employees. GENOMIC VISION is a public listed company listed in compartment C of Euronext’s regulated market in Paris (Euronext: GV – ISIN: FR0011799907).
FORWARD LOOKING STATEMENT

This press release contains implicitly or explicitly certain forward-looking statements concerning Genomic Vision and its business. Such forward-looking statements are based on assumptions that Genomic Vision considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the “Risk Factors” section of the reference document dated March 29, 2019 filed with the AMF under reference number R19-004, available on the web site of Genomic Vision (www.genomicvision.com) and to the development of economic conditions, financial markets and the markets in which Genomic Vision operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Genomic Vision or not currently considered material by Genomic Vision. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Genomic Vision to be materially different from such forward-looking statements.

This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for Genomic Vision shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.